A citation-based method for searching scientific literature


List of co-cited articles
54 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
M G Kris, D R Camidge, G Giaccone, T Hida, B T Li, J O'Connell, I Taylor, H Zhang, M E Arcila, Z Goldberg,[...]. Ann Oncol 2015
180
13

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
406
13

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Daniel B Costa, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D Wilner. J Clin Oncol 2011
444
13

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
13


Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer.
Li Li, Yubo Wang, Lin Jiao, Caiyu Lin, Conghua Lu, Kejun Zhang, Chen Hu, Junyi Ye, Dadong Zhang, Haiyan Wu,[...]. Cancer Lett 2019
35
6

Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma.
Mohammad Jafarnejad, Richard J Sové, Ludmila Danilova, Adam C Mirando, Yu Zhang, Mark Yarchoan, Phuoc T Tran, Niranjan B Pandey, Elana J Fertig, Aleksander S Popel. NPJ Syst Biol Appl 2019
9
11

Understanding and targeting resistance mechanisms in NSCLC.
Julia Rotow, Trever G Bivona. Nat Rev Cancer 2017
399
6

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.
N Girard, C S Sima, D M Jackman, L V Sequist, H Chen, J C-H Yang, H Ji, B Waltman, R Rosell, M Taron,[...]. Eur Respir J 2012
77
6

Drug resistance in cancer: an overview.
Genevieve Housman, Shannon Byler, Sarah Heerboth, Karolina Lapinska, Mckenna Longacre, Nicole Snyder, Sibaji Sarkar. Cancers (Basel) 2014
997
6

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Alessandro Leonetti, Sugandhi Sharma, Roberta Minari, Paola Perego, Elisa Giovannetti, Marcello Tiseo. Br J Cancer 2019
271
6

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
6

The epidemiology of lung cancer.
Patricia M de Groot, Carol C Wu, Brett W Carter, Reginald F Munden. Transl Lung Cancer Res 2018
246
6

EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers.
Min Pan, Henrik Schinke, Elke Luxenburger, Gisela Kranz, Julius Shakhtour, Darko Libl, Yuanchi Huang, Aljaž Gaber, Miha Pavšič, Brigita Lenarčič,[...]. PLoS Biol 2018
27
6

Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
Yanmei Yi, Shanshan Zeng, Zhaotong Wang, Minhua Wu, Yuanhuan Ma, Xiaoxia Ye, Biao Zhang, Hao Liu. Biochim Biophys Acta Mol Basis Dis 2018
48
6

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Min Yuan, Li-Li Huang, Jian-Hua Chen, Jie Wu, Qing Xu. Signal Transduct Target Ther 2019
109
6

Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments.
Yoojung Kwon, Misun Kim, Hyun Suk Jung, Youngmi Kim, Dooil Jeoung. Cancers (Basel) 2019
37
6

MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer.
Ying Zhang, Lu Guo, Yuhuan Li, Gui-Hai Feng, Fei Teng, Wei Li, Qi Zhou. Mol Cancer 2018
178
6

Significance of TRIM29 and β-catenin expression in non-small-cell lung cancer.
Zhi-Yi Zhou, Guo-Yi Yang, Jing Zhou, Min-Hong Yu. J Chin Med Assoc 2012
30
6

Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution.
Loukia G Karacosta, Benedict Anchang, Nikolaos Ignatiadis, Samuel C Kimmey, Jalen A Benson, Joseph B Shrager, Robert Tibshirani, Sean C Bendall, Sylvia K Plevritis. Nat Commun 2019
75
6

How to interpret LC3 immunoblotting.
Noboru Mizushima, Tamotsu Yoshimori. Autophagy 2007
6

Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines.
Tianxiang Chen, Jizhuang Luo, Yu Gu, Jia Huang, Qingquan Luo, Yunhai Yang. Thorac Cancer 2019
29
6

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies.
Xuan Zhu, Lijie Chen, Ling Liu, Xing Niu. Front Oncol 2019
70
6

CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Kenichi Suda, Isao Murakami, Hui Yu, Jihye Kim, Aik-Choon Tan, Hiroshi Mizuuchi, Leslie Rozeboom, Kim Ellison, Christopher J Rivard, Tetsuya Mitsudomi,[...]. Mol Cancer Ther 2018
22
6

Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion.
Alessandra M Richardson, Lauren S Havel, Allyson E Koyen, Jessica M Konen, John Shupe, W G Wiles, W David Martin, Hans E Grossniklaus, Gabriel Sica, Melissa Gilbert-Ross,[...]. Clin Cancer Res 2018
106
6

The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis.
Hengrui Liang, Zhenkui Pan, Wei Wang, Chengye Guo, Difei Chen, Jianrong Zhang, Yiyin Zhang, Shiyan Tang, Jianxing He, Wenhua Liang. J Thorac Dis 2018
25
6

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
Nitin Roper, Anna-Leigh Brown, Jun S Wei, Svetlana Pack, Christopher Trindade, Chul Kim, Olivia Restifo, Shaojian Gao, Sivasish Sindiri, Farid Mehrabadi,[...]. Cell Rep Med 2020
37
6

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
D Planchard, Y Loriot, F André, A Gobert, N Auger, L Lacroix, J C Soria. Ann Oncol 2015
216
6

Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer.
Ji Yeon Kim, Woo Jeong Lee, Ha Young Park, Ahrong Kim, Dong Hoon Shin, Chang Hun Lee. J Pathol Transl Med 2018
5
20

Control of autophagy by oncogenes and tumor suppressor genes.
M C Maiuri, E Tasdemir, A Criollo, E Morselli, J M Vicencio, R Carnuccio, G Kroemer. Cell Death Differ 2009
316
6

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.
Yuxin Mu, Xuezhi Hao, Ke Yang, Di Ma, Shouzheng Wang, Ziyi Xu, Junling Li, Puyuan Xing. Target Oncol 2019
16
6

LC3-positive structures are prominent in autophagy-deficient cells.
Gautam Runwal, Eleanna Stamatakou, Farah H Siddiqi, Claudia Puri, Ye Zhu, David C Rubinsztein. Sci Rep 2019
88
6



An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.
Tamkin Ahmadzada, Steven Kao, Glen Reid, Michael Boyer, Annabelle Mahar, Wendy A Cooper. J Clin Med 2018
31
6




Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment.
Tianli Zhang, Bing Wan, Yuan Zhao, Chuling Li, Hongbing Liu, Tangfeng Lv, Ping Zhan, Yong Song. Transl Lung Cancer Res 2019
42
6


Selective autophagy mediated by autophagic adapter proteins.
Terje Johansen, Trond Lamark. Autophagy 2011
6

Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases.
Halla Vidarsdottir, Lena Tran, Björn Nodin, Karin Jirström, Maria Planck, Per Jönsson, Johanna S M Mattsson, Johan Botling, Patrick Micke, Hans Brunnström. Hum Pathol 2019
17
6

Resisting Resistance: Targeted Therapies in Lung Cancer.
Jessica J Lin, Alice T Shaw. Trends Cancer 2016
89
6

Epithelial-to-mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy.
Mau Ern Poh, Chong Kin Liam, Kein Seong Mun, Chee Shee Chai, Chee Kuan Wong, Jiunn Liang Tan, Thian Chee Loh, Ka Kiat Chin. Thorac Cancer 2019
4
25


Novel steps in the autophagic-lysosomal pathway.
Frank Saetre, Linda Korseberg Hagen, Nikolai Engedal, Per O Seglen. FEBS J 2015
14
7

Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.
Xun Yuan, Hua Wu, Na Han, Hanxiao Xu, Qian Chu, Shiying Yu, Yuan Chen, Kongming Wu. J Hematol Oncol 2014
142
6

Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.
Guanhua Rao, Mariaelena Pierobon, In-Kyu Kim, Wei-Hsun Hsu, Jianghong Deng, Yong-Wha Moon, Emanuel F Petricoin, Yu-Wen Zhang, Yisong Wang, Giuseppe Giaccone. Sci Rep 2017
38
6

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Kang-Seo Park, Mark Raffeld, Yong Wha Moon, Liqiang Xi, Caterina Bianco, Trung Pham, Liam C Lee, Tetsuya Mitsudomi, Yasushi Yatabe, Isamu Okamoto,[...]. J Clin Invest 2014
75
6



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.